In a small, preliminary study, an experimental vaccine provoked a strong immune response against precancerous cells in women treated for cervical lesions that can progress to cancer.
Most cases of cervical cancer are caused by infection with two types of human papillomavirus, or HPV. Some women who have precancerous cervical lesions associated with the Type 16 and Type 18 strains of HPV are able to fight them off without medical intervention. They do so by producing high levels of immune cells called killer T-cells.
Read the full story: http://nyti.ms/SQVgeX
Source: The New York Times